
Please try another search
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company’s PentixaFor is being developed as a diagnostic tool for primary aldosteronism, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
Name | Age | Since | Title |
---|---|---|---|
Hakim Bouterfa | 62 | - | Member of the Supervisory Board |
Marcus Quinkler | 57 | 2024 | Member of the Supervisory Board |
Ken Herrmann | 48 | 2024 | Member of the Supervisory Board |
Harald Hasselmann | 58 | 2024 | Supervisory Board Member |
Jens Giltsch | 59 | 2024 | Member of the Supervisory Board |
Andreas Eckert | 65 | 2024 | Chairman of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review